NCT01732211 is a Phase 2 clinical trial of PD 0360324 in Pulmonary Sarcoidosis, sponsored by Pfizer.

Who is sponsoring NCT01732211?

NCT01732211 is sponsored by Pfizer.

What drugs are being tested in NCT01732211?

Interventions in NCT01732211: PD 0360324, Normal Saline for injection.

What condition does NCT01732211 study?

NCT01732211 studies Pulmonary Sarcoidosis.

Is NCT01732211 still recruiting?

NCT01732211 is currently terminated. Last updated 6 January 2020.

Are results published for NCT01732211?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-01-06 · How we verify

NCT01732211

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis

Terminated Phase 2 Results posted Last updated 6 January 2020

What this trial tests

Phase 2 trial testing PD 0360324 in Pulmonary Sarcoidosis in 1 participant. Terminated before completion.

Timeline

15 March 2013

Primary endpoint
23 September 2013

23 September 2013

Quick facts

Lead sponsor	Pfizer
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	basic science
Enrollment	1
Start date	15 March 2013
Primary completion	23 September 2013
Estimated completion	23 September 2013
Sites	5 locations across United States

Drugs / interventions tested

PD 0360324 — full drug profile →
Normal Saline for injection — full drug profile →

Conditions studied

Pulmonary Sarcoidosis — all drugs for Pulmonary Sarcoidosis →

Sponsor

Pfizer — full company profile →

Who can join

Adults 21 to 75, any sex, with Pulmonary Sarcoidosis. Patients with the condition only — healthy volunteers not accepted.

Adverse events — posted to ClinicalTrials.gov

Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

PD 0360324 100 mg Q2W / 150 mg Q2W

Serious: 0/1 (0%)

Deaths: —

Other adverse events (2 terms — click to expand)

Reaction	System	PD 0360324 100 mg Q2W / 15…
Eye swelling	Eye disorders	—
Musculoskeletal chest pain	Musculoskeletal and connective tissue disorders	—

Data from ClinicalTrials.gov NCT01732211 adverse events section.

Sponsor's own description

The study proposes to evaluate the safety, tolerability, and efficacy of PD 0360324 in subjects with chronic pulmonary sarcoidosis inadequately treated with standard of care therapies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of PD 0360324

Trials testing the same drug.

NCT02554812 — A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) · Phase 1, PHASE2 · terminated

Other recruiting trials for Pulmonary Sarcoidosis

Currently open trials in the same condition.

NCT06853834 — Comparative Diagnostic Yield of Endobronchial Cryo Biopsy vs Forceps Biopsy in Patients With Suspected Sarcoidosis · NA · recruiting
NCT05415137 — Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis · Phase 3 · active not recruiting
NCT00001532 — Role of Genetic Factors in the Development of Lung Disease · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01732211 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 6 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01732211.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing